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INTRODUCTION
Gene transfer for therapeutic purposes is now an established and 
promising treatment strategy in disease paradigms where conven-
tional treatments are unavailable or inadequate. Despite decades 
of frustratingly slow progress, several recent successes1–3 demon-
strate the vital and transformative role that gene therapy will play in 
the future of medicine. In general, the field has progressed beyond 
proof-of-principle into a new focus on research questions related 
to clinical practicality. Delivery of genetic payloads remains, as it 
has always been, the greatest challenge to realizing the full clini-
cal potential of gene therapy. With clinically efficacious gene trans-
fer now a demonstrated reality, current research is exploring more 
nuanced delivery issues, such as changes in intracellular program-
ming that may occur as the result of gene transfer to target tissues.
Nonviral gene transfer overcomes one of the most vexing chal-
lenges to clinical implementation of gene therapy, namely the 
introduction of viral vector antigens into host cells and tissues.4–6 
However, due to the vanguard role viral vectors have historically 
played in advancing gene therapy from the theoretical to clinical 
reality, research examining host response to nonviral vectors has 
understandably lagged. Because nonviral vectors lack the protein 
antigens necessary to initiate classical humoral or cell-mediated 
extracellular immunity, these vectors have often been assumed 
to be modestly or negligibly immunogenic provided they encode 
a therapeutic protein that is native to the host.7 This assumption 
is reasonable as far as it goes, but intracellular host response to 
nonviral vectors has not been well studied and may present an addi-
tional challenge for gene therapy.
Our group has successfully applied the principle of ultrasound-
assisted gene transfer (UAGT) to the salivary gland,8 relying upon 
the biophysical effect referred to as sonoporation9 to allow a plas-
mid to physically transit the membranes of salivary gland epithelial 
cells. This gene transfer model relies upon bloodless cannulation of 
the salivary duct, and infusion of the vector and microbubbles into 
the intraductal labyrinth of the salivary gland.10 As such, the volume, 
concentration, and composition of the gene transfer solution can be 
precisely controlled and isolated from blood or mucosal defenses, 
allowing us to parse out vector-specific physiological responses in 
the target tissue. UAGT does not stimulate inflammation or cellu-
lar infiltration of the gland, and thus, we can profile the proteome 
of the homogenized organ without concern for contributions from 
exogenous cells.
In this study, we took advantage of these characteristics of sali-
vary gland gene transfer as a model system to explore the impact of 
nonviral gene transfer upon the proteome of the gland. Gel-based 
proteomic profiling has limitations,11 but it provides a global, unbi-
ased look at gene transfer–associated changes in organ physiology 
as manifested in the proteome. Our goal was to understand the 
overall magnitude of changes in the proteomic profile of the gland, 
if any, following UAGT with first-generation plasmids and advanced 
minicircle12,13 vectors. We theorize that subcellular proteomic altera-
tions associated with nonviral gene transfer to the salivary gland will 
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In this study, we compared gene transfer efficiency and host response to ultrasound-assisted, nonviral gene transfer with a conven-
tional plasmid and a minicircle vector in the submandibular salivary glands of mice. Initially, we looked at gene transfer efficiency 
with equimolar amounts of the plasmid and minicircle vectors, corroborating an earlier report showing that minicircle is more 
efficient in the context of a physical method of gene transfer. We then sought to characterize the physiological response of the 
salivary gland to exogenous gene transfer using global proteomic profiling. Somewhat surprisingly, we found that sonoporation 
alone, without a gene transfer vector present, had virtually no effect on the salivary gland proteome. However, when a plasmid vec-
tor was used, we observed profound perturbations of the salivary gland proteome that compared in magnitude to that seen in a 
previous report after high doses of adeno-associated virus. Finally, we found that gene transfer with a minicircle induces only minor 
proteomic alterations that were similar to sonoporation alone. Using mass spectrometry, we assigned protein IDs to 218 gel spots 
that differed between plasmid and minicircle. Bioinformatic analysis of these proteins demonstrated convergence on 68 known 
protein interaction pathways, most notably those associated with innate immunity, cellular stress, and morphogenesis.
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give us broadly generalizable insights into intracellular response to 
nonviral vectors in a variety of target tissues and thus advance our 
understanding of the potential for vector-associated intracellular 
toxicity in gene therapy.
ReSUlTS
Generation of minicircle vectors based upon pCMV-GL3enh
The expression cassette from pCMV-GL3enh was successfully 
transferred to the pMC.BESPX-MCS1 parental vector and con-
firmed by sequence analysis. This vector was used to transform the 
ZYCY10P3S2T bacterial strain, and transformed bacteria were then 
exposed to arabinose, resulting in excision and recircularization 
of the cytomegalovirus (CMV)-GL3enh minicircle and the release 
and degradation of the parental backbone. The structure of the 
isogenic pCMV-GL3enh plasmid and CMV-GL3enh minicircle are 
shown in Figure 1a. Figure 1b shows bands of the appropriate size 
for the CsCl-purified products of the excision reaction, including the 
7710bp parental vector and the 3290bp minicircle.
UAGT to the salivary gland results in global but heterogeneous 
gene transfer and does not result in cellular infiltration or tissue 
disruption
In our initial report describing UAGT to the mouse salivary gland,8 
we reported that the process appeared to be stochastic and without 
preference to cell type, but our analysis was somewhat confounded 
by autofluorescence of the salivary gland tissue. To improve our 
approach, we relied upon HRP-based staining of tissue sections 
and utilized gene transfer of human α-1-antitrypsin (A1AT) as the 
marker and the results are shown in Figure 2. Some background 
staining was observed in the extracellular matrix, but there was no 
background staining in any of the cellular elements when the A1AT 
antibody was excluded (right lower panel). Specific staining for the 
marker transgene was observed in both ductal (left lower panel) 
and acinar cells (right upper panel). Globally, staining was observed 
throughout the gland with occasional regions of intense staining 
(upper left panel).
Additionally, we utilized these sections to evaluate whether UAGT 
of a foreign gene results in cellular infiltration or tissue disruption of 
the mouse salivary gland. This question was particularly pertinent 
to our present study because if cellular infiltration is absent, we can 
assume that proteomic changes that occur in the tissue as a result 
of plasmid or minicircle gene transfer are primarily attributable to 
the intracellular response of native salivary gland cells to the vec-
tors. The lower right panel in Figure 2 shows negative control (i.e., 
staining without antibody) tissue sections serial to those stained for 
A1AT, demonstrating a lack of cellular infiltration and no noticeable 
disruption of tissue architecture following UAGT with a plasmid vec-
tor encoding A1AT. Formal scoring of the study tissue for these indi-
ces was performed by a blinded oral pathologist (Dr. Paul Edwards) 
Figure 1 Generation of Minicircle plasmid DNA. (a) The expression cassette was excised from the first-generation plasmid vector, pCMV-GL3enh and 
ligated into the parental plasmid, pMC-Gl3-Enhancer. After the addition of arabinose, the parental vector is cleaved, and the progeny minicircle (C) and 
backbone, containing the bacterial origin of replication and antibiotic resistance, are religated. The backbone sequence contains several engineered 
I-SecI restriction sites that ultimately lead to the degradation of the parental DNA but not the Minicircle DNA. (b) DNA gel of the minicircle prep shows 
the intact parental vector (7.7 kb) in the absence (−) of arabinose, and the minicircle in the presence (+) of arabinose (3.29 kb, note the absence of the 
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and results indicated no difference between naive control glands 
and experimental (data not shown).
Minicircle vectors mediate superior UAGT relative to first-
generation plasmids
In initial testing of our minicircle vectors, we used bioluminescent 
imaging following UAGT to compare the gene transfer efficiency of 
the minicircle to our conventional pCMV-GL3enh vector, a vector 
system that is routinely utilized in our laboratory. Using our standard 
UAGT conditions, with eqimolar concentrations of pCMV-GL3enh or 
pMC-CMV-GL3enh, we found that the minicircle was more efficient 
in the magnitude of transgene expression (see Figure 3). This find-
ing is consistent with an earlier report of a similar phenomenon fol-
lowing electrotransfer to muscle.14
Sonoporation without gene transfer exerts negligible effects upon 
salivary gland protein expression
The mechanism underlying UAGT is thought to occur primarily 
through the formation of transient pores in the cell membrane 
created by the inertial cavitation that occurs when microbubbles 
implode in the presence of an acoustic field of the appropriate 
frequency and power.15–18 While not fatal to cells under optimal 
conditions, we assumed that the biophysical insult resulting 
from sonoporation would elicit a physiological response within 
target cells that would be reflected in the proteomic profile. 
Using gel-based proteomic profiling (see Figure 4 for diagram of 
workflow), we sought to measure the magnitude of this response 
for later comparison with UAGT. Figure 5b shows the composite 
proteomic fingerprint of a mouse salivary gland, created by the 
DeCyder software (GE Healthcare, Piscataway, NJ) by integrating 
eight salivary gland samples, taken from mice 24 hours after 
sonoporation alone, versus a composite proteome of a naive 
gland integrated across six samples. To our surprise, sonopora-
tion alone exerted only minor effects (>6%) upon the proteomic 
profile of the gland using our standard thresholds.
Figure 2 Immunohistochemical analysis of mouse salivary glands 24 hours following ultrasound-assisted gene transfer (UAGT) of a α-1-antitrypsin-
expressing plasmid. Sections stained in the presence of the polyclonal anti-A1AT antibody (upper left) show a global but heterogeneous staining 
pattern that labels both ductal (D) and acinar (A) cells. Sections stained in the absence of the antibody (lower right panel) reveal some background 
staining in the interstitial connective tissues, but cell bodies are clear of staining. Bar = 50 µm.
Figure 3 Quantification of luciferase activity 24 hours following gene 
transfer to the salivary gland. Average total flux (photons/second) 
is measured by the charge-coupled devices camera system over a 
60-second sampling period. Gene transfer with ultrasound-assisted gene 
transfer (UAGT)/plasmid (n = 6), UAGT/minicircle (n = 8), and adenovirus 
at a dose of 1 × 108 viral particles (n = 6) is compared. “*” indicates 
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Proteomic profiling of salivary gland following UAGT reveals major 
alterations in the proteomic profile that are attributable to the 
plasmid backbone
We have previously shown that adeno-associated virus vector-
mediated gene transfer to the salivary gland results in profound 
alterations of the salivary gland proteome in the absence of his-
tological manifestations of inflammation or tissue damage.19 After 
finding that sonoporation alone had little effect upon the proteome 
of the salivary gland, we wondered whether the addition of a plas-
mid vector to sonoporation (i.e., UAGT) would have a detectable 
effect on the proteome. Figure 5c shows results of this experiment. 
We found >25% of all proteins were altered 24 hours after UAGT rel-
ative to naive gland. These results indicate that plasmid-mediated 
gene transfer exerts a profound effect upon the mouse salivary 
gland, approaching in magnitude that seen with virus-mediated 
gene transfer.
UAGT with minicircles eliminates >95% of the proteomic 
alterations associated with first-generation plasmids
Based upon these results, we could not be certain whether these 
effects were due to noneukaryotic sequences in the plasmid back-
bone, generalized effects of foreign gene transfer, or a combination 
of the two. In order to parse these potential contributions to the 
observed phenomenon, we performed UAGT dose of minicircle vec-
tor equimolar to that of plasmid used in the experiment reported in 
Figure 5c. The minicircle contained an expression cassette identical 
in all respects to the first-generation plasmid. Figure 5d shows results 
of these experiments, demonstrating that the minicircle construct 
obviates the proteomic alterations seen with the first-generation 
plasmid, making it nearly indistinguishable from sonoporation alone.
Proteins identified and pathway analysis
In order to make an initial exploration into the organ response to 
plasmid-mediated gene transfer, we picked 378 spots that were 
altered in plasmid versus naive but not altered in minicircle ver-
sus naive. Of these, 237 were conclusively identified using matrix-
assisted laser desorption/ionization time-of-flight mass spec-
trometry, and their identities are listed in Table 1. Briefly, protein 
identification by peptide mass fingerprinting was done using the 
Bruker Daltonics FLEX series software includes several engines 
called flexAnalysis, BioTools, and Matrix Science MASCOT Search. 
The MASCOT search utility reports the highest probable hits with 
as a histogram of Mowse scores. Positive protein ID’s were reported 
only in those cases where one hit, and only one hit, achieved a 
Mowse score greater than 73. All proteins identified thusly were 
then brought back to BioTools and the MS spectrum was annotated 
with matched peptides as an additional quality control step. In cases 
where multiple hits exceeded a Mowse score of 73, those proteins 
were not reported. Table 1 therefore reflects proteins identified with 
the highest level of confidence, and 141 of the protein spots picked 
were omitted due to failure to meet this standard.
Using the GO-Elite pathway analysis tool,20 the proteins identified 
were compiled into 68 common interaction pathways, containing 
2 or more identified proteins, and these are listed in Table 2. Visual 
output of the pathway analysis highlighting our proteins-of-interest 
are presented in full in the Supplementary Material. Of the 68 path-
ways implicated, 18 contained >3 of our proteins of interest, and 
several of these are reviewed in the discussion below.
DISCUSSION
UAGT to the salivary gland presents a unique model system in 
which to answer fundamental questions of nonviral vectorology. 
The salivary gland is an epithelium-derived, encapsulated structure 
that communicates with the oral cavity via the salivary duct. This 
anatomy facilitates delivery of gene transfer material via bloodless 
cannulation of the salivary duct and retrograde infusion. Because 
Figure 4 Diagram of our bioinformatic workflow. (a) Comparison of two 
randomly paired samples from the two groups to be compared (e.g., naive 
and ultrasound-assisted gene transfer/plasmid) is carried out by labeling 
one sample with Cy3 and the other sample with Cy5 and running on the 
same gel to obtain a difference image. Cy dyes are then swapped and a 
second get is run to correct for Cy dye intensity differences. (b) The step 
shown in (a) is repeated for each randomly paired sample set and the 
difference images are integrated across all eight sample pairings. Analysis 
of variance is performed on a spot-by-spot basis to arrive at a final dataset 
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the contents of the intraductal labyrinth of the salivary gland can be 
controlled by external manipulation, we are able to precisely con-
trol the gene transfer conditions. This in turn allows us to parse out 
the effects on organ physiology of various viral and nonviral vectors 
using sonoporation. We previously utilized this technique to exam-
ine the effect of adeno-associated virus-mediated gene transfer on 
the mouse salivary gland proteome19 and documented profound 
global proteomic alterations that were dose dependent, even in the 
absence of extracellular inflammatory host response.
We were initially surprised to find that sonoporation alone, with-
out the addition of a gene transfer vector, had minimal effects upon 
the proteome of the salivary gland. We had assumed that the iner-
tial cavitation phenomenon underlying sonoporation would have 
substantial short-term effects upon membrane physiology and 
possibly structural proteins, even though we have documented 
that UAGT does not cause overt histological damage to the salivary 
gland. Nevertheless, our observation that sonoporation alone does 
not substantially alter the proteome presents a unique opportunity 
to study organ responses to various nonviral vectors, specifically 
first-generation plasmids and minicircles, in isolation from other 
confounding factors.
The limitations of gel-based proteomic profiling have been 
described11 and include the following: (i) failure to visualize high 
pI proteins, (ii) a focus on magnitude of change in spot intensity, 
which will not detect small but potentially important changes in 
proteins such as phosphorylation of G proteins, and (iii) inability 
to visualize hydrophobic (e.g., membrane-associated) or highly 
glycosylated proteins. Thus, our results are best viewed as the 
selected pieces of a much larger puzzle that implicate some 
pathways in the host response to plasmid vectors but may not 
detect all pathways of importance. These limitations notwith-
standing, there is no doubt that these results accurately reflect 
the relative magnitude of proteomic alterations following plas-
mid versus minicircle gene transfer, and these results impli-
cate the plasmid backbone, whether due to its size, sequence, 
or both, as a major stimulator of innate immunity even in the 
absence of viral antigens. It should be noted that while efforts 
were made to ensure that the plasmid and the minicircle vector 
were as isogenic as possible, with the sequence differing only in 
the backbone region, they were prepared in different Escherichia 
coli lines, raising the possibility that methylation patterns and 
secondary structure may differ between the two vectors.
In instances where our analysis revealed clustering of our iden-
tified proteins in common pathways, the convergence was upon 
innate immunity, including most prominently Type 2 interferon, 
tumor necrosis factor-α/NF-κB, and Wnt. Additional innate sig-
naling pathways implicated were interleukins 2, 3, 4, 5, 6, and 7, 
as well as Toll-like receptor signaling. Our findings may be con-
sidered relative to an earlier study by Mann et al.21 that docu-
mented changes in gene expression 1, 4, 7, and 14 days following 
gene electrotransfer to muscle tissue. Mann et al. also reported 
upregulation of Type 2 interferon and a number of interleukins 
(2, 6, and 12) following plasmid electrotransfer, a finding that is 
consistent with our results and may reflect the downstream gene 
expression consequences of the early proteomic changes that 
we have described. Notably, Mann et al. also reported that the 
Figure 5 Composite proteomic profiles of salivary glands following gene transfer with nonviral vectors. (a) naive salivary gland, (b) salivary gland 24 
hours following sonoporation in the absence of a plasmid vector, (c) salivary gland 24 hours following sonoporation in the presence of pCMV-GL3enh 
plasmid, (d) and salivary gland 24 hours following sonoporation in the presence of the CMV-GL3enh minicircle. Calculated differences as determined 
by DeCyder analysis (threshold = 2, P value = <0.05) are presented in the table, with each experimental condition being compared to naive.
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2′-5′-oligoadenylate synthase 3 OAS3_MOUSE







72 kDa inositol polyphosphate 5-phosphatase INP5E_MOUSE
A disintegrin and metalloproteinase with 
thrombospondin motifs 4
ATS4_MOUSE
Abhydrolase domain-containing protein 
FAM108C1
F108C_MOUSE
Actin-binding Rho-activating protain ABRA_MOUSE
Actin-related protein T2 ACTT2_MOUSE
Activator of apoptosis harakiri HRK_MOUSE
Acylphosphatase-1 ACYP1_MOUSE
Adenylsuccinate synthetase isozyme 1 PURA1_MOUSE
ADP-ribosylation factor-like protein 4D ARL4D_MOUSE
AF4/FMR2 family member 1 AFF1_MOUSE
Alcohol dehydrogenase [NADP(+)] AK1A1_MOUSE
Aldehyde dehydrogenase family 3 member B1 AL3B1_MOUSE
α-N-acetylgalactosaminidase NAGAB_MOUSE
Alsin ALS2_MOUSE




Ankyrin repeat domain-containing protein 24 ANR24_MOUSE
Aspartate-tRNA ligase cytoplasmic SYDC_MOUSE
Ataxin-7 ATX7_MOUSE
ATP-binding cassette subfamily B member 8 ABCB8_MOUSE
Autophagy-related protein 2 homolog B ATG2B_MOUSE
Bcl10-interacting CARD protein BINCA_MOUSE
Bcl-2 homologous antagonist/killer BAK_MOUSE
BEN domain-containing protein 3 BEND3_MOUSE
β-1,4 N-acetylgalactosan-minyltransferase 1 B4GN1_MOUSE
β-1-syntrophin SNTB1_MOUSE
BTB/POZ domain containing protein KCTD11 KCD11_MOUSE
Calcium uptake protein 1, mitochondrial MICU1_MOUSE
Calcium-transporting ATPase Type 2C member 1 AT2C1_MOUSE
Calpain-7 CAN7_MOUSE
cAMP-specific 3′,5′-cyclic phosphodiesterase 4A PDE4A_MOUSE
CAP-Gly domain-containing linker protein 1 CLIP1_MOUSE
Casein kinase II subunit α CSK22_MOUSE
CB1 cannabinoid receptor-interaction protein 1 CNRP1_MOUSE
CD48 antigen CD48_MOUSE
Centrisomal protein of 170 kDa protein B C170B_MOUSE
Cholesterol 7-α-monooxygenase CP7A1_MOUSE
Choline dehydrogenase, mitochondrial CHDH_MOUSE
Coatomer subunit β COPB2_MOUSE
Coiled-coil domain-containing protein 148 CC148_MOUSE
Coiled-coil domain-containing protein 164 CC164_MOUSE
COMM domain-containing protein 9 COMD9_MOUSE
COP9 signalosome complex subunit 4 CSN4_MOUSE
C-type lectin domain family 2 member I CLC2I_MOUSE
Cystatin-C CYTC_MOUSE
Cytochrome b-c1 complex subunit 9 QCR9_MOUSE
Cytochrome p450 CP1A2_MOUSE
Cytochrome P450 2C50 CY250_MOUSE
Cytoplasmic dynein 1 light intermediate chain 1 DC1L1_MOUSE
Cytoplasmic dynein 2 heavy chain 1 DYHC2_MOUSE
DCC-interacting protein 13-β DP13B_MOUSE
Disintegrin and metalloproteinase domain-
containing protein 15
ADA15_MOUSE
DNA replication licensinf factor MCM7 MCM7_MOUSE
DnaJ homolog subfamily C member 28 DJC28_MOUSE
Docking protein 1 DOK1_MOUSE
Docking protein 6 DOK6_MOUSE




E3 SUMO-protein ligase PIAS4 PIAS4_MOUSE
E3 ubiquitin-protein ligase MARCH3 MARH3_MOUSE





Ectoderm-neural cortex protein 2 ENC2_MOUSE
Ecto-NOX disulfide-thiol exchanger 2 ENOX2_MOUSE
Electron transfer flavoprotein subunit α, 
mitochondrial
ETFA_MOUSE
Ephrin type-B receptor 1 EPHB1_MOUSE
Ethanolamine-phosphate cytidylyltransferase PCY2_MOUSE
Exophilin-5 EXPH5_MOUSE




Fragile X mental retardation syndrome-related 
protein 1
FXR1_CRIGR
Fragile X mental retardation syndrome-related 
protein 2
FXR2_MOUSE
G patch domain-containing protein 2 GPTC2_MOUSE
γ-crystallin A CRGA_MOUSE
GAS2-like protein 2 GA2L2_MOUSE
GDNF-inducible zinc finger protein 1 GZF1_MOUSE
General transcription factor 3C polypeptide 4 TF3C4_MOUSE
Table 1 Continued
7
Proteomic profiling of nonviral gene transfer
R Geguchadze et al.
Molecular Therapy — Methods & Clinical Development (2014) © 2014 The American Society of Gene & Cell Therapy









Neutrophil cytosol factor 1 NCF1_MOUSE
Nuclear pore complex protein Nup85 NUP85_MOUSE
Nucleolar GTP-binding protein 1 NOG1_MOUSE
Nucleolar protein 16 NOP16_MOUSE
Nucleolar transcription factor 1 UBF1_MOUSE
Opalin OPALI_MOUSE
Pantothenate kinase 4 PANK4_MOUSE
Paraspeckle component 1 PSPC1_MOUSE
Peptidyl-prolyl cis-trans isomerase FKBP5 FKBP5_MOUSE
Peroxiredoxin-1 PRDX1_MOUSE
Phenylalanine-4-hydroxylase PH4H_MOUSE
Phosphate carrier protein mitochondrial MPCP_MOUSE
Phosphatidylinositol 3-kinase catalytic subunit 
Type 3
PK3C3_MOUSE
Phosphatidylinositol transfer protein β isoform PIPNB_MOUSE
Phosphorylated CTD-interacting factor 1 PCIF1_MOUSE
Plexin-B2 PLXB2_MOUSE
Poly (a) polymerase γ PAPOG_MOUSE
Poly(U)-specific endoribonuclease ENDOU_MOUSE
Prickle-like protein PRIC1_MOUSE
Probable ATP-dependent RNA helicase DDX6 DDX6_MOUSE






Protein kinase C delta-binding protein PRDBP_MOUSE
Protein naked cuticle homolog 1 NKD1_MOUSE
Protein N-terminal asparagine amidohydrolase NTAN1_MOUSE
Protein RER1 RER1_MOUSE
Protein TCL1B1 TCLB1_MOUSE
Putative ATP-dependent RNA helicase TDRD9 TDRD9_MOUSE








Pyruvate dehydrogenase (lipoamide) kinase 
isozyme 2 mitochondrial
PDK2_MOUSE
Pyruvate dehydrogenase (lipoamide) kinase 
isozyme 3 mitochondrial
PDK3_MOUSE
Glial fibrillary acidic protein GFAP_MOUSE
Glyceraldehyde-3-phosphate dehydrogenase G3P_MOUSE
Glycine receptor subunit α-4 GLRA4_MOUSE
Glycogen phosphorylase PYGM_MOUSE
Glyoxalase domain-containing protein 5 GLOD5_MOUSE
Golgi SNAP receptor complex member 1 GOSR1_MOUSE
Golgin subfamily A member 3 GOGA3_MOUSE
GRB2-associated and regulator of MAPK 
protein-like
GAREL_MOUSE
GS homeobox 1 GSX1_MOUSE
GTPase Hras RASH_MOUSE
Guanine nucleotide-binding protein subunit 
β-2-like 1
GBLP_MOUSE
Heat shock cognate 71 kDa protein HSP7C_MOUSE
Hemojuvelin RGMC_MOUSE
Huntingtin-interacting protein 1-related protein HIP1R_MOUSE
Hydrocephalus-inducing protein HYDIN_MOUSE
Ig heavy chain V region J558 HVM13_MOUSE
Influenza virus NS1BP-binding protein homolog NS1BP_MOUSE
Inhibitor of nuclear factor κ-B kinase subunit 
epsilon
IKKE_MOUSE
Initiation factor 4A-III IF4A3_MOUSE




Intraflagellar transport protein 57 IFT57_MOUSE
Intraflagellar transport protein 74 homolog IFT74_MOUSE
Kelch-like protein 36 KLH36_MOUSE
Kinesin-like protein KLP6 KLP6_MOUSE
Kinocilin KNCN_MOUSE
Laminin subunit α-5 LAMA5_MOUSE
Lens epithelial cell protein LEP503 LENEP_MOUSE
Leucine-rich repeat-containig protein 23 LRC23_MOUSE
Leucine-rich repeat-containing protein 7 LRRC7_MOUSE
Long-chain-fatty-acid-CoA ligase ACSL6_MOUSE
Macoilin MACOI_MOUSE
MAGE-like protein 2 MAGL2_MOUSE







Microphage scavenger receptor Types 1 and 2 MSRE_MOUSE
Mitogen-activated kinase M3KL4_MOUSE
Mitotic-spindle organizing protein 2 MZT2_MOUSE
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effects of electroporation with a plasmid vector present were ~20-
fold greater than electroporation alone, strikingly similar to our 
observations. The identities of proteins identified as being substan-
tially altered as a result of UAGT with first-generation plasmid vec-
tors, but not with minicircle vectors, present an interesting albeit 
incomplete picture of intracellular host response to nonviral vectors 
that highlights innate immune response and morphogenesis.
It should be appreciated that the present state of open-
source pathway analysis in proteomics is extremely limited, with 
Wikipathways only coming online in 2008. In fact, of the 237 pro-
teins (Table 1) identified as significantly altered between naive 
salivary gland and salivary gland following UAGT with a first-
generated plasmid vector, only a few dozen were classified to 
known Wikipathways by the GO-ELITE analysis. Of these, a clear 
signaling cascade could be observed in only two cases, that of 
the Sos1-Hras1-Araf axis (leading to MEK/ERK activation)22 and 
the TRIF-Traf3-IKKepsilon axis (stimulated by Tlr3/4 and leading to 
Irf3 activation).23 This demonstrates in stark detail both the power 
and limitations of whole-proteome profiling. With respect to the 
former, we can generate “hits”, allowing us to focus on implicated 
pathways for more nuanced analysis of cell biology. With respect 
to the latter, the vast majority of our data cannot yet be reduced 
to a known pathway and thus teaches us relatively little beyond a 
quantitative measure of the extent of global proteomic alteration 
stimulated by the plasmid backbone.
Tyrosine-protein phosphatase non-receptor 
Type 12
PTN12_MOUSE
Tyrosine-protein phosphatase non-receptor 
Type 13
PTN13_MOUSE
U7 snRNA-associated Sm-like protein LSm11 LSM11_MOUSE
Ubiquitin carboxyl-terminal hydrolase 13 UBP13_MOUSE
Ubiquitin carboxyl-terminal hydrolase 36 UBP36_MOUSE
UBX domain-containing protein UBXN8_MOUSE





Uncharacterized protein C11orf89 homolog CK089_MOUSE
Uncharacterized protein C2orf47 homolog CB047_MOUSE
Uncharacterized protein C9orf114 homolog CI114_MOUSE
Uncharacterized protein C9orf172 homolog CI172_MOUSE
Upoplakin-1b UPK1B_MOUSE
UV-stimulated scaffold protein A UVSSA_MOUSE
Vacuolar fusion protein MON1 homolog B MON1B_MOUSE
Vomeronasal Type 2 receptor 1 V2R1_MOUSE
V-set and immuniglobulin domain-containing 
protein 8
VSIG8_MOUSE
V-type proton ATPase subunit B VATB2_MOUSE
WAP four-disulfide core domain protein 6B WFC6B_MOUSE
WD repeat-containig protein 93 WDR93_MOUSE
Xin actin-binding repeat-containing protein2 XIRP2_MOUSE
Zinc finger protein 182 ZN182_MOUSE
Zinc finger protein 90 ZEP90_MOUSE
Rap guanine nucleotide exchange factor 5 RPGF5_MOUSE
Ras-related protein Rab-19 RAB19_MOUSE
Receptor-transporting protein 4 RTP4_MOUSE
Receptor-type tyrosine-protein phosphatase U PTPRU_MOUSE
Regulator of G-protein signaling 4 RGS4_MOUSE
Rho GTPase-activating protein 1 RHG01_MOUSE
Sarcolemmal membrane-associated protein SLMAP_MOUSE
Semaphorin-3A SEM3A_MOUSE
Semaphorin-7A SEM7A_MOUSE
Seminal vesicle secretory protein 5 SVS5_MOUSE
Septin-2 SEPT2_MOUSE
Septin-8 SEPT8_MOUSE
Serine/threonine-protein kinase ICK ICK_MOUSE
Serine/threonine-protein kinase Nek11 NEK11_MOUSE
Serine/threonine-protein kinase Nek5 NEK5_MOUSE
Serine/threonine-protein kinase PLK4 PLK4_MOUSE




Small nuclear ribonucleoprotein-associated 
protein N
RSMN_MOUSE
Son of sevenless homolog 1 SOS1_MOUSE
Spermatogenesis-associated protein 7 homolog SPAT7_MOUSE
SRC kinase signaling inhibitor 1 SRCN1_MOUSE
Sulfite oxidase, mitochondrial SUOX_MOUSE
SUN domain-containing protein 1 SUN1_MOUSE
Synaptotagmin-6 SYT6_MOUSE
T-box transcription factor TBX21 TBX21_MOUSE
Testin TES_MOUSE
TIR domain-containing adapter molecule 1 TCAM1_MOUSE
Torsin-1B TOR1B_MOUSE




Trans-2-enoyl-CoA reductase mitochondrial MECR_MOUSE
Transketolase-like protein 2 TKTL2_MOUSE




Tubulin β-2B chain TBB2B_MOUSE
Tudor domain-containing protein 3 TDRD3_MOUSE
Tumor protein p63-regulated gene 1 protein TPRG1_MOUSE
Tyrosine-protein kinase ABL1 ABL1_MOUSE
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If we accept the premise that gene transfer should have the most 
minimal collateral effects upon the target tissue as possible, then 
these results clearly demonstrate advantages of minicircle vectors 
as gene transfer agents in the salivary gland, both with regard to 
gene transfer efficiency and what might be termed “intracellular 
toxicity”. Our group is developing a nonviral approach to attempt 
to mimic positive reports of therapeutic efficacy in a human clini-
cal trial utilizing adenovirus-mediated gene transfer of aquaporin-1 
to the salivary glands of humans suffering from radiation-induced 
xerostomia.24,25 In this effort, the translational relevance of these 
findings should be directly relevant to the design of nonviral vec-
tors for salivary gland gene therapy. Further, a number of clinical 
trials involving plasmid-mediated gene transfer to such tissues as 
skin, muscle, and heart have shown promising results.26–29 It remains 
to be seen whether other organs or tissues show a similar intracel-
lular reaction to plasmid vectors, but this seems likely to be the 
case, as Mann et al.21 suggest. Going forward, the clinical impor-
tance of these intracellular responses must be evaluated, particu-
larly in applications requiring episodic readministration of plasmid-
mediated gene transfer. The assumption that plasmid-mediated 
Table 2 Pathways identified
WikiPathway 
ID
3pp Specification Number of 
protein(s)
WP310 mRNA processing 12
WP246 TNF-α NF-κB signaling pathway 7
WP1763 PluriNetWork 7
WP407 Kit receptor signaling pathway 6
WP572 EGFR1 signaling pathway 6
WP6 Integrin-mediated cell adhesion 5
WP65 Insulin signaling 5
WP539 Wnt signaling pathway NetPath 5
WP1253 Type 2 interferon signaling (IFNG) 5
WP85 Focal adhesion 4
WP251 MAPK cascade 4
WP274 B cell receptor signaling pathway 4
WP373 IL-3 signaling pathway 4
WP431 Nuclear receptors in lipid metabolism 
and toxicity
4
WP480 T-cell receptor signaling pathway 4
WP1261 ErbB signaling pathway 4
WP2087 miRNA regulation of DNA damage 
response
4
WP79 Tryptophan metabolism 3
WP190 Cell cycle 3
WP216 Striated muscle contraction 3
WP387 IL-6 signaling pathway 3
WP434 TCA cycle 3
WP488 α6-β4 integrin signaling pathway 3
WP493 MAPK signaling pathway 3
WP662 Amino acid metabolism 3
WP1251 Metapathway biotransformation 3
WP1254 Apoptosis 3
WP1262 Aflatoxin B1 metabolism 3
WP1267 Senescence and autophagy 3
WP1271 Toll-like receptor signaling 
pathway:KEGG
3
WP1983 Splicing factor NOVA-regulated 
synpatic proteins
3
WP2185 Purine metabolism:KEGG-mmu00230 3
WP2292 Chemokine signaling pathway:KEGG-
mmu04062
3
WP88 Toll-like receptor signaling 2
WP93 IL-4 signaling pathway 2
WP151 IL-5 signaling pathway 2
WP163 Cytoplasmic ribosomal proteins 2
WP193 Signaling of hepatocyte growth factor 
receptor
2
WP232 G Protein signaling pathways 2
WP240 Alanine and aspartate metabolism 2
WP258 TGF-β receptor signaling pathway 2
WP297 IL-7 signaling pathway 2
WP336 Fatty acid biosynthesis 2
WP339 ESC pluripotency pathways 2
WP350 p38 MAPK signaling pathway (BioCarta) 2
WP413 G1 to S cell cycle control 2
WP447 Adipogenesis 2
WP450 IL-2 signaling pathway 2
WP458 Inflammatory response pathway 2
WP519 Proteasome degradation 2
WP523 Regulation of actin cytoskeleton 2
WP544 Circadian exercise 2
WP571 FAS pathway and stress induction of 
HSP regulation
2
WP723 Wnt signaling pathway and 
pluripotency
2
WP730 Glutathione and one carbon 
metabolism
2
WP1244 Estrogen signalling 2
WP1249 EPO receptor signaling 2
WP1264 Estrogen metabolism 2
WP1270 Endochondral ossification 2
WP1274 Cytochrome P450 2
WP1496 Oxidative damage 2
WP1560 MicroRNAs in cardiomyocyte 
hypertrophy
2
WP1770 One carbon metabolism and related 
pathways
2
WP2074 Neural crest differentiation 2
WP2310 PodNet: protein-protein interactions in 
the podocyte
2
WP2316 PPAR signaling pathway:KEGG-
mmu03320
2
WP2432 Spinal cord injury 2
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gene transfer has minimal impact upon the host immune response 
should be reconsidered, and a minimalist approach to vector con-
struction (e.g., minicircles or mini-intronic plasmids)30 is appealing 




All animal studies were conducted at Allegheny General Hospital, 
Pittsburgh, PA and were approved by the Institutional Animal 
Care and Use Committee. Wild-type C57/BL6 animals were bred at 
Allegheny General Hospital and male mice were used for all studies.
Construction and preparation of vectors
The pGL3-enhancer vector was purchased from Promega 
(Madison, WI) and a canonical CMV promoter was inserted 
in the multiple cloning site. The entire expression cassette, 
including promoter, luciferase open reading frame, polyA, and 
enhancer were subcloned into the pAAV-MCS (Stratagene, La 
Jolla, CA) vector, resulting in pCMV-GL3enh. The expression 
cassette was then excised from pCMV-GL3enh and ligated 
into  the  pMC.BESPX-MCS1 vector (System Biosciences, Mountain 
View, CA; #MN100A-1), resulting in pMC-CMV-GL3enh (both vectors 
shown in Figure 1a). Full sequence information for both of these vec-
tors is provided in the Supplementary Material. Minicircle construc-
tion was performed in the ZYCY10P3S2T bacterial strain per manu-
facturer’s instructions. Both vectors were prepared for experiments 
by purification using CsCl gradient centrifugation. Absorbance 
ratios were 1.89 (260/280) and 1.86 (260/230) for the plasmid and 
1.98 (260/280) and 1.47 (260/230) for the minicircle. Endotoxin levels 
were measured in the final preps using a ToxinSensor kit (GenScript, 
Piscataway, NJ) according to manufacturer’s instructions. Endotoxin 
levels in the plasmid and minicircle were 0.082 and 0.041 EU/ml, 
respectively and did not differ substantially from a plasmid purified 
using a PureYield Plasmid Mini kit (0.097 EU/ml) including the endo-
toxin removal step (Promega, Madison, WI).
UAGT to salivary glands
UAGT was performed as previously described.8 Briefly, the subman-
dibular duct was cannulated bilaterally and a 50 µl solution con-
taining 15% v/v Definity microbubbles and 1 g/l of plasmid vector 
(or the equimolar equivalent of minicircle vector) in phosphate-
buffered saline (PBS) was infused. Bubbles were destroyed by 4 × 30 
seconds bursts from a Sonigene device (Visualsonics, Toronto, ON, 
Canada) set for 1 MHz, 50% duty cycle, and 2 W/cm2, with 10 sec-
onds between pulses. Following the four pulses, the emitter was 
withdrawn and the animal allowed to rest for 10 minutes before the 
catheter was removed.
Bioluminescent imaging
Mice were anesthetized and injected intraperitoneally with the 
D-Luciferin substrate (Caliper Life Sciences, Hopkinton, MA) at a 
dose of 150 mg/10 g body weight. The mice were then placed in the 
IVIS Lumina II chamber containing a cryogenically cooled charge-
coupled device camera to quantify photons spontaneously emitted 
by the animal. A standardized area-of-interest centered on the sali-
vary gland was applied and total flux within this area was quanti-
fied as the average photons emitted/second/cm2 over a 60-second 
sampling period.
Histological analysis
A cohort of animals (n = 6) underwent UAGT with a plasmid encod-
ing human α-1-antitrypsin and were sacrificed 48 hours later and 
salivary gland removed and fixed in 5% paraformaldehyde in PBS 
pH 7.4 overnight. After processing for paraffin embedding, slices of 
5 µm were cut per sample. The tissues were then deparaffinized and 
rehydrated. Hydrated tissues were subjected to antigen retrieval by 
incubating in 20 g/l proteinase K in buffer TE pH 8.0 at 37 °C during 
10 minutes. The endogenous peroxidase was quenched for 10 min-
utes using 3% H2O2 in methanol followed by washing in PBS buffer 
pH 7.4. Prior to incubation with primary antibody, the sections were 
blocked with 10% fetal bovine serum, 04% saponin, 0.02% NaN3 in 
PBS buffer pH 7.4. A rabbit anti-A1AT polyclonal antibody (Dako, 
Glostrup, Denmark) diluted 1/800 in blocking buffer was incubated 
with the sections overnight at 4 °C. After a PBS wash step to remove 
unbound antibody, the detection of the primary antibody was 
realized using Histostain Plus 3rd Gen IHC detection kit (Invitrogen, 
Carlsbad, CA). Before mounting in CitraMount medium, the nuclei 
were counterstained with Mayer’s hematoxylin. The slides were 
scanned in a VS120 microscope slide scanner (Olympus, Japan) and 
pictures were taken using an objective of ×20 and ×40. For the his-
topathological analysis, the deparaffinized sections were stained 
using hematoxylin/eosin following standard procedures.
Proteomic profiling using 2-D difference gel electrophoresis
Twenty-four hours after UAGT, animals were sacrificed and salivary 
glands were harvested and homogenized in ice-cold T-PER (Pierce, 
Rockford, IL) with a protease inhibitor cocktail (Roche Diagnostics, 
Mannheim, Germany). Difference gel electrophoresis analysis was 
performed as previously described in detail.19 Technical details of 
difference gel electrophoresis analysis were duplicated exactly as 
described in this earlier report, including dye swapping and manual 
quality control of DeCyder output. Figure 4 graphically illustrates 
the workflow of the proteomic profiling technique.
Image analysis
Gel analysis was performed using DeCyder DIA and BVA engines 
(GE Healthcare, Piscataway, NJ), a 2-D gel analysis software package 
designed specifically for the analysis of multiple difference gel elec-
trophoresis experiments. This software package utilizes proprietary 
software to manage background subtraction, in-gel normaliza-
tion, gel artifact removal, gel-to-gel matching, and statistical anal-
ysis. Manual input is restricted to setting threshold, P values, and 
manual spot checking as a final quality-control step to ensure that 
automated exclusion and inclusion of spots is appropriate. The esti-
mated number of spots for each codetection procedure was set to 
4,000. As recommended, an exclusion filter was applied to remove 
spots with a slope greater than one in order to reject spots that were 
likely to be contaminated with dust particles. A fixed value of 2.0 
(±2) was used as the threshold to determine differentially expressed 
proteins, and P values were set at <0.05 to determine statistically 
significant differences between groups.
Protein spot extraction and identification
Based upon DeCyder analysis, 378 spots were chosen for extrac-
tion from the gels using an Ettan Spot Piker automated robot arm. 
This device integrates with the DeCyder software and allows precise 
extraction of spots-of-interest without manual input. Extracted spots 
were then in-gel digested. Briefly, gel slices (1.4 mm in diameter) 
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were soaked in 200 µl of 25 mmol/l ammonium bicarbonate and 
incubated at room temperature for 15 minutes. The supernatant was 
removed and discarded and this step was repeated three times. Next, 
gel slices were immersed in 200 µl 100% acetonitrile and incubated 
at room temperature for 30 seconds. The supernatant was removed 
and discarded. Remaining liquid in the gel pieces was removed by 
SpeedVac for 5 minutes and then rehydrated in trypsin-containing 
solution (Promega; #V5280) for 20 minutes at a concentration of 
20 ng/ml and then covered above with 25 mmol/l ammonium 
bicarbonate. Protein was digested at 37 °C overnight (16–18 hours). 
Tryptic peptides were extracted from gel slices using 0.2 µl C18 resin 
ZipTip procedure (EMD Millipore, Billerica, MA; #ZTC18M960) accord-
ing to manufacturer’s protocol. Final extract was eluted with TA30 
solvent (30:70 [v/v] acetonitrile: 0.1% trifluoroacetic acid in water) 
containing a-cyano-4-hydroxycinnamic acid at 10 mg/ml (Bruker 
Daltonik GmbH, Bremen, Germany; #255344) and applied on ground 
steel matrix-assisted laser desorption target plate. A Bruker matrix-
assisted laser desorption/ionization time-of-flight ultraflextreme 
mass spectrometer was used to characterize the protein fingerprint 
spectra. Spectra were queried on an in-house MASCOT server to 
determine protein identities, and estimated pI and molecular weight 
were determined from gels and considered in positively identifying 
proteins where spectra alone identified multiple identity candidates.
Pathway and protein function analysis
GO-Elite (http://www.genmapp.org/go_elite) was used for the inte-
gration of identified proteins with biomolecular interaction net-
works (WikiPathways).31 All calculations and visual integration of 
the network with expression profiles (the final gene list) was done 
with probe sets at P < 0.05. For the interpretation, crosschecking, 
and visualization of the data, we also used AmiGO Term Enrichment 
and GO Slimmer (http://www.geneontology.org), GO Term Finder 
Cluster, and Tree View to perform cluster analysis using Euclidean 
distance algorithms of log-transformed, normalized raw data.
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